Differential pathological response to preoperative chemotherapy across breast cancer intrinsic subtypes

Hiromitsu Jinno, Sachiko Matsuda, Tetsu Hayashida, Maiko Takahashi, Shigemichi Hirose, Tadashi Ikeda, Yuukou Kitagawa

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Breast cancer is a heterogeneous disease with a diversity of clinical behaviors. The purpose of this study was to evaluate the utility of breast cancer intrinsic subtypes in the prediction of pathological complete response (pCR) in a cohort of breast cancer patients receiving preoperative chemotherapy. Methods: Patients with stage II/III breast cancer received 4 cycles of XT (capecitabine and docetaxel) followed by 4 cycles of FEC (fluorouracil, epirubicin, and cyclophosphamide) as preoperative chemotherapy. Tumors were classified as luminal A, luminal B, luminal/HER2, HER2, basal-like, or non-basal-like triple negative by immunohistochemical analysis in core needle biopsy samples at baseline. Results: The overall pCR rate was 11.9% (12/101). Multivariate analysis showed that intrinsic subtype was an independent factor to predict pCR. With luminal A patients as the reference group, luminal B (OR = 16.39; 95% CI 1.44-185.88; p = 0.024), HER2 (OR = 14.73; 95% CI 1.19-180.84; p = 0.035), and basal-like (OR = 13.27; 95% CI 1.27-138.79; p = 0.031) patients had a significantly higher likelihood of pCR. Conclusion: The present data indicate that intrinsic subtypes may be useful predictive biomarkers of pCR in breast cancer patients treated with preoperative chemotherapy.

Original languageEnglish
Pages (from-to)364-370
Number of pages7
JournalChemotherapy
Volume58
Issue number5
DOIs
Publication statusPublished - 2013 Jan

Fingerprint

Breast Neoplasms
Drug Therapy
docetaxel
Large-Core Needle Biopsy
Epirubicin
Fluorouracil
Cyclophosphamide
Multivariate Analysis
Biomarkers
Neoplasms

Keywords

  • Breast cancer
  • Chemotherapy
  • Intrinsic subtype
  • Predictive factor

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery

Cite this

Differential pathological response to preoperative chemotherapy across breast cancer intrinsic subtypes. / Jinno, Hiromitsu; Matsuda, Sachiko; Hayashida, Tetsu; Takahashi, Maiko; Hirose, Shigemichi; Ikeda, Tadashi; Kitagawa, Yuukou.

In: Chemotherapy, Vol. 58, No. 5, 01.2013, p. 364-370.

Research output: Contribution to journalArticle

Jinno, Hiromitsu ; Matsuda, Sachiko ; Hayashida, Tetsu ; Takahashi, Maiko ; Hirose, Shigemichi ; Ikeda, Tadashi ; Kitagawa, Yuukou. / Differential pathological response to preoperative chemotherapy across breast cancer intrinsic subtypes. In: Chemotherapy. 2013 ; Vol. 58, No. 5. pp. 364-370.
@article{59d71d44762346c0a4b61fe91bd7f7ee,
title = "Differential pathological response to preoperative chemotherapy across breast cancer intrinsic subtypes",
abstract = "Background: Breast cancer is a heterogeneous disease with a diversity of clinical behaviors. The purpose of this study was to evaluate the utility of breast cancer intrinsic subtypes in the prediction of pathological complete response (pCR) in a cohort of breast cancer patients receiving preoperative chemotherapy. Methods: Patients with stage II/III breast cancer received 4 cycles of XT (capecitabine and docetaxel) followed by 4 cycles of FEC (fluorouracil, epirubicin, and cyclophosphamide) as preoperative chemotherapy. Tumors were classified as luminal A, luminal B, luminal/HER2, HER2, basal-like, or non-basal-like triple negative by immunohistochemical analysis in core needle biopsy samples at baseline. Results: The overall pCR rate was 11.9{\%} (12/101). Multivariate analysis showed that intrinsic subtype was an independent factor to predict pCR. With luminal A patients as the reference group, luminal B (OR = 16.39; 95{\%} CI 1.44-185.88; p = 0.024), HER2 (OR = 14.73; 95{\%} CI 1.19-180.84; p = 0.035), and basal-like (OR = 13.27; 95{\%} CI 1.27-138.79; p = 0.031) patients had a significantly higher likelihood of pCR. Conclusion: The present data indicate that intrinsic subtypes may be useful predictive biomarkers of pCR in breast cancer patients treated with preoperative chemotherapy.",
keywords = "Breast cancer, Chemotherapy, Intrinsic subtype, Predictive factor",
author = "Hiromitsu Jinno and Sachiko Matsuda and Tetsu Hayashida and Maiko Takahashi and Shigemichi Hirose and Tadashi Ikeda and Yuukou Kitagawa",
year = "2013",
month = "1",
doi = "10.1159/000343663",
language = "English",
volume = "58",
pages = "364--370",
journal = "Chemotherapy",
issn = "0009-3165",
publisher = "S. Karger AG",
number = "5",

}

TY - JOUR

T1 - Differential pathological response to preoperative chemotherapy across breast cancer intrinsic subtypes

AU - Jinno, Hiromitsu

AU - Matsuda, Sachiko

AU - Hayashida, Tetsu

AU - Takahashi, Maiko

AU - Hirose, Shigemichi

AU - Ikeda, Tadashi

AU - Kitagawa, Yuukou

PY - 2013/1

Y1 - 2013/1

N2 - Background: Breast cancer is a heterogeneous disease with a diversity of clinical behaviors. The purpose of this study was to evaluate the utility of breast cancer intrinsic subtypes in the prediction of pathological complete response (pCR) in a cohort of breast cancer patients receiving preoperative chemotherapy. Methods: Patients with stage II/III breast cancer received 4 cycles of XT (capecitabine and docetaxel) followed by 4 cycles of FEC (fluorouracil, epirubicin, and cyclophosphamide) as preoperative chemotherapy. Tumors were classified as luminal A, luminal B, luminal/HER2, HER2, basal-like, or non-basal-like triple negative by immunohistochemical analysis in core needle biopsy samples at baseline. Results: The overall pCR rate was 11.9% (12/101). Multivariate analysis showed that intrinsic subtype was an independent factor to predict pCR. With luminal A patients as the reference group, luminal B (OR = 16.39; 95% CI 1.44-185.88; p = 0.024), HER2 (OR = 14.73; 95% CI 1.19-180.84; p = 0.035), and basal-like (OR = 13.27; 95% CI 1.27-138.79; p = 0.031) patients had a significantly higher likelihood of pCR. Conclusion: The present data indicate that intrinsic subtypes may be useful predictive biomarkers of pCR in breast cancer patients treated with preoperative chemotherapy.

AB - Background: Breast cancer is a heterogeneous disease with a diversity of clinical behaviors. The purpose of this study was to evaluate the utility of breast cancer intrinsic subtypes in the prediction of pathological complete response (pCR) in a cohort of breast cancer patients receiving preoperative chemotherapy. Methods: Patients with stage II/III breast cancer received 4 cycles of XT (capecitabine and docetaxel) followed by 4 cycles of FEC (fluorouracil, epirubicin, and cyclophosphamide) as preoperative chemotherapy. Tumors were classified as luminal A, luminal B, luminal/HER2, HER2, basal-like, or non-basal-like triple negative by immunohistochemical analysis in core needle biopsy samples at baseline. Results: The overall pCR rate was 11.9% (12/101). Multivariate analysis showed that intrinsic subtype was an independent factor to predict pCR. With luminal A patients as the reference group, luminal B (OR = 16.39; 95% CI 1.44-185.88; p = 0.024), HER2 (OR = 14.73; 95% CI 1.19-180.84; p = 0.035), and basal-like (OR = 13.27; 95% CI 1.27-138.79; p = 0.031) patients had a significantly higher likelihood of pCR. Conclusion: The present data indicate that intrinsic subtypes may be useful predictive biomarkers of pCR in breast cancer patients treated with preoperative chemotherapy.

KW - Breast cancer

KW - Chemotherapy

KW - Intrinsic subtype

KW - Predictive factor

UR - http://www.scopus.com/inward/record.url?scp=84870293172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870293172&partnerID=8YFLogxK

U2 - 10.1159/000343663

DO - 10.1159/000343663

M3 - Article

VL - 58

SP - 364

EP - 370

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

IS - 5

ER -